Leqvio

Inclisiran, the active ingredient in Leqvio, is a small interfering RNA (siRNA) therapeutic presented as a 284 mg/1 mL solution for subcutaneous injection. It is indicated for lowering low‑density lipoprotein cholesterol in adults with heterozygous familial hypercholesterolemia, clinical atherosclerotic cardiovascular disease, or primary hypercholesterolemia.

GNH USA supplies Leqvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products that meet EU regulatory standards.

Leqvio acts on the PCSK9 pathway to provide additional LDL‑cholesterol reduction for patients with established lipid disorders. - Heterozygous familial hypercholesterolemia: reduces LDL‑cholesterol levels when added to statin therapy. - Clinical atherosclerotic cardiovascular disease: provides further LDL‑cholesterol lowering to help lower cardiovascular risk. - Primary hypercholesterolemia: lowers LDL‑cholesterol in patients requiring additional lipid reduction beyond standard therapy.

Leqvio is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Injection site pain or erythema. - Nasopharyngitis. - Headache. - Diarrhea. - Fatigue.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema). - Persistent elevation of liver enzymes. - Unexplained muscle pain or weakness that may indicate rhabdomyolysis.

Leqvio requires careful consideration of patient-specific factors before initiation. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown safety; consider potential effects on the infant. - Renal impairment: use with caution; monitor renal function. - Hepatic impairment: no dose adjustment required, but monitor liver enzymes. - Concomitant lipid‑lowering therapy: assess for additive LDL reduction and potential muscle symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leqvio may interact with other therapies that affect lipid metabolism or immune function.

Major Interactions (Avoid): - Live vaccines: avoid simultaneous administration as immune response may be altered. - Strong immunosuppressants: may diminish therapeutic effect of inclisiran.

Moderate Interactions (Monitor Closely): - Statins: monitor for additive LDL‑cholesterol reduction and possible muscle-related side effects. - PCSK9 monoclonal antibodies: concurrent use generally not recommended; evaluate clinical necessity. - Anticoagulants: observe for any changes in bleeding risk when combined with lipid‑lowering therapy.